Injuries & Orthopedics
Best Peptides for Nerve Injury & Neuropathy: Clinical Evidence (2026)
A clinical, evidence-graded ranking of the peptides studied for nerve injury and neuropathy — ARA-290, Cerebrolysin, BPC-157 and Cortagen — separating genuine human RCT data from animal-only signal.
ARA-290 (cibinetide)CerebrolysinBPC-157CortagenSmall-fiber neuropathy
The quick verdict
An evidence-first ranking of the four peptides studied for nerve repair — from ARA-290's genuine human RCT data down to single-lab animal signal — graded honestly, with 2026 FDA and WADA status.
- Best overall
- ARA-290 (Cibinetide) — The only peptide with double-blind, placebo-controlled human trials showing objective small-nerve-fiber regeneration (corneal nerve fiber area + skin GAP-43+ fibers) at 4 mg SC daily — Grade B, Phase 2.
- Best value
- Address the underlying driver — No peptide is FDA-approved for neuropathy; the most defensible, lowest-risk step is correcting the cause — glucose control, B12/toxin status, compression, autoimmune triggers — plus guideline pharmacotherapy.
- Best for Peripheral diabetic neuropathy symptoms (research context)
- ARA-290 (Cibinetide) — In type 2 diabetic neuropathy it improved neuropathic symptoms and corneal nerve-fiber density without raising hemoglobin — the strongest human peripheral-neuropathy signal in this list.
How we evaluated
PeptideVox ranks each peptide strictly by the strength of its nerve-injury evidence, separating randomized human trials from animal-only signal and from anecdotal or vendor claims. We prioritize objective nerve-regeneration endpoints (nerve-fiber density, conduction) over symptom scores, weight independent replication over single-lab or sponsor-associated work, and grade down any preclinical-only compound regardless of mechanistic appeal. Dosing is reported only as it appears in published literature and registered trials, never as a recommendation.
- Human trial quality. Presence and rigor of randomized, double-blind, placebo-controlled human trials specifically in nerve injury or neuropathy — with objective regeneration endpoints weighted above symptom-only measures.
- Independent replication. Whether findings are reproduced beyond a single laboratory or sponsor; sponsor-correlated or single-network evidence is weighted down.
- Mechanistic plausibility. A coherent, documented mechanism for nerve repair (e.g., innate-repair-receptor signaling, angiogenesis, neurotrophic mimicry) — necessary but never sufficient for a grade.
- Safety & regulatory status. Long-term human safety data, FDA status, and anti-doping status (WADA), plus product-quality risk from the unregulated research-chemical market.
Rating scale: 1–5 stars, mapped to evidence grade: Grade B human Phase 2 RCT ≈ 4; single small human RCT ≈ 3; consistent multi-model animal data ≈ 2.5; single-lab animal data ≈ 2. Grades are never inflated from preclinical to human.
Last verified .
At a glance
| # | Name | Evidence | Rating | Best for | Pricing |
|---|---|---|---|---|---|
| 1 | ARA-290 (Cibinetide) | B | 4.0 | Understanding the strongest genuine human evidence for peptide-driven nerve regeneration (small-fiber neuropathy research context) | Not FDA-approved; research chemical only |
| 2 | Cerebrolysin | B | 3.0 | Readers weighing the one small peripheral-neuropathy RCT against a large but contested central-nerve-injury literature | Not FDA-approved in the U.S.; prescription drug abroad |
| 3 | BPC-157 | C | 2.5 | Understanding the most-hyped 'nerve repair' peptide honestly — strong animal biology, unproven in humans | Not FDA-approved; research chemical only |
| 4 | Cortagen | C | 2.0 | Seeing how a genuine but single-lab animal finding is honestly graded below replicated evidence | Not FDA-approved; research chemical only |
ARA-290 (Cibinetide)
The only peptide with human nerve-regeneration RCTs
ARA-290 (cibinetide) is the only peptide in this list with randomized, double-blind, placebo-controlled human trials specifically in neuropathy — and uniquely, those trials measured objective small-nerve-fiber regeneration rather than symptoms alone. In the pivotal Phase 2b dose-ranging trial in sarcoidosis-associated small-fiber neuropathy (NCT02039687; n=64; 4 mg subcutaneous daily for 28 days), the 4 mg dose significantly increased corneal nerve fiber area (placebo-corrected +697 µm², P=0.012 — roughly a 23% increase) and increased skin GAP-43+ regenerating intraepidermal nerve fibers (P=0.035), with the two regeneration markers correlating with each other and with the 6-minute walk test. In type 2 diabetic neuropathy (n=48), it improved neuropathic symptoms and increased corneal nerve-fiber density in the low-baseline subgroup, all without raising hemoglobin or hematocrit — a deliberate design feature that avoids EPO's thrombosis risk. Mechanistically it selectively activates the innate repair receptor (an EPO-receptor / β-common-receptor heterocomplex) upregulated under injury, triggering anti-apoptotic and anti-inflammatory signaling. The honest limits are real: all evidence is Phase 2, from a single Leiden/Araim research network, never advanced to Phase 3 or approval, and the celebrated pain relief was inconsistently superior to placebo.
Strengths
- Only peptide with double-blind human RCTs showing objective nerve-fiber regeneration (corneal + skin), replicated across sarcoidosis and diabetic neuropathy
- Non-erythropoietic by design — improved outcomes without raising hemoglobin/hematocrit, avoiding EPO's thrombosis risk
- Coherent, documented mechanism via the innate repair receptor tied directly to a human regeneration readout
- Generally well tolerated in trials (mild injection-site reactions, transient headache)
Weaknesses
- Phase 2 only — small samples, concentrated in a single research network, never advanced to Phase 3 or FDA approval
- Pain relief was inconsistently superior to placebo even in positive trials; long-term safety beyond 4–8 weeks is uncharacterized
- Prohibited at all times under WADA S2.1; sold only as an unregulated research chemical
- Best for
- Understanding the strongest genuine human evidence for peptide-driven nerve regeneration (small-fiber neuropathy research context)
- Pricing
- Not FDA-approved; research chemical only
Source: Culver/Dahan et al., IOVS 2017; Brines et al., Mol Med 2015 (PMC4365069)
Cerebrolysin
Largest human-RCT footprint — but mostly for central nerve injury
Cerebrolysin has the largest human-RCT footprint of any compound here, but those large trials are for central nerve injury — acute ischemic stroke and traumatic brain injury — where the independent evidence is mixed-to-negative, while its peripheral-neuropathy human evidence is thin. The directly on-topic data are limited to a small German double-blind placebo-controlled trial (Biesenbach et al.): in about 25 patients with long-standing painful diabetic peripheral neuropathy, a 10-day Cerebrolysin course reduced pain on the visual-analog scale from 4.7 to 3.1 (roughly a 34% reduction, P<0.001) versus a non-significant 12% reduction on placebo. That is a single small study with a symptom — not nerve-regeneration — endpoint, graded B at best. For context, its central trials include CARS (post-stroke motor recovery) and the CAPTAIN TBI series, but the independent 2023 Cochrane review of acute ischemic stroke (7 RCTs, 1,773 patients) found little to no difference in death or death-or-dependence and a possible increase in non-fatal serious adverse events. Cerebrolysin is a porcine-brain-derived peptide/amino-acid mixture whose specific active fraction and pharmacokinetics remain undefined, and trial sponsorship correlates strongly with positive results.
Strengths
- Largest human randomized-trial base of any compound here, including a directly on-topic (if small) peripheral-neuropathy RCT
- On-topic diabetic-neuropathy trial showed a statistically significant ~34% VAS pain reduction versus non-significant placebo change
- Approved for clinical use in 45+ countries with a long, characterized adverse-event profile
- Proposed neurotrophic mechanism (BDNF/NGF/GDNF/CNTF mimicry) supporting neuronal survival and plasticity
Weaknesses
- Peripheral-neuropathy human evidence is a single small symptom-only trial — not to be conflated with the large, contested CNS literature
- Independent 2023 Cochrane stroke review found no functional benefit and a possible non-fatal serious-adverse-event signal; positive trials are largely sponsor-associated
- Contraindicated in epilepsy; porcine-derived (anaphylaxis risk); active fraction and pharmacokinetics undefined
- Best for
- Readers weighing the one small peripheral-neuropathy RCT against a large but contested central-nerve-injury literature
- Pricing
- Not FDA-approved in the U.S.; prescription drug abroad
Source: Ziganshina et al., Cochrane CD007026 2023 (PMC10565895); Biesenbach review
BPC-157
Deepest animal nerve data — but zero human nerve trials
Among the animal-only candidates, BPC-157 has the deepest and most internally consistent preclinical nerve-injury dataset — but human nerve-repair evidence is nonexistent. In a rat traumatic-nerve-injury study (transected sciatic nerve with anastomosis, plus a 7-mm nerve-gap/tubing model), BPC-157 improved healing clinically (no autotomy), functionally (Sciatic Functional Index walking recovery), electrophysiologically (increased motor action potentials on EMG), and histomorphometrically (increased density and size of regenerative fibers, improved myelination); in the 7-mm gap model — which usually causes permanent deficit — local BPC-157 raised motor action potentials. In a rat spinal-cord-injury model (L2–L3 compression), a single intraperitoneal dose produced progressive motor recovery, resolved spasticity by day 15, and reduced white-matter axonal and gray-matter motoneuron loss out to 360 days. The proposed mechanism is the VEGFR2–Akt–eNOS angiogenic/nitric-oxide axis plus rescue of somatosensory neurons. But no completed human randomized trial exists for any indication, let alone neuropathy; total published human exposure is on the order of a couple dozen subjects in uncontrolled safety pilots, with no validated human pharmacokinetics. The first registered Phase 2 RCT is for hamstring strain, not nerve injury, and has not reported.
Strengths
- Deepest, most internally consistent rat nerve-injury dataset — sciatic transection, 7-mm gap, and spinal-cord-injury models
- Convergent readouts (function, EMG, histology, myelination) rather than a single endpoint, with effects sustained to 360 days in the spinal model
- Coherent pro-angiogenic mechanism (VEGFR2–Akt–eNOS) plausibly relevant to nerve perfusion and axonal regrowth
- Favorable animal safety profile and reported oral/gastric-juice stability
Weaknesses
- No completed human nerve-injury trial and no validated human pharmacokinetics — all human 'nerve repair' claims are extrapolation from rodents (Grade C)
- Pro-angiogenic mechanism (VEGFR2/EGR-1) is a theoretical caution in active or prior malignancy; product-quality risk from research-chemical vials
- Prohibited at all times under WADA S0 with documented athlete sanctions; unsettled 2026 FDA compounding status
- Best for
- Understanding the most-hyped 'nerve repair' peptide honestly — strong animal biology, unproven in humans
- Pricing
- Not FDA-approved; research chemical only
Cortagen
Single-lab rat signal, unreplicated, no human trials
Cortagen ranks last because its nerve-regeneration signal is concrete but unreplicated outside its originating Russian research group, and there are no human trials. In male Wistar rats with transected and sutured sciatic nerve, Cortagen (the Ala-Glu-Asp-Pro tetrapeptide from the Khavinson program) at 10 micrograms per kilogram intramuscular for 10 days increased the growth rate and conduction velocity of regenerating fibers by about 27% and 40% respectively, with a follow-up reporting persistence of the effect into the remyelination phase at five months. It also shows rat-model brain neuroprotection in chronic cerebral ischemia (reduced lipid peroxidation, preserved antioxidant activity) and measurable tissue gene-expression shifts on microarray, consistent with its hypothesized nuclear gene-modulation mechanism. However, there are no human RCTs for any indication. The widely repeated claim that Cortagen has a therapeutic effect on post-traumatic recovery of human peripheral nerve traces to introductory assertions in review or vendor material, not a retrievable controlled human trial — which should be read as Grade D when applied to humans. The entire favorable literature originates from one network, much of it in lower-impact or hard-to-access journals, and the nuclear-DNA-binding mechanism remains hypothesis-grade.
Strengths
- Concrete rat sciatic-nerve regeneration signal (+27% growth rate, +40% conduction velocity) at a defined 10 µg/kg IM × 10 days regimen
- Reported persistence of the effect into the remyelination phase at five months
- Supporting rat neuroprotection data in chronic cerebral ischemia (reduced lipid peroxidation, preserved antioxidant activity)
Weaknesses
- Single-lab, single-network animal data, unreplicated externally and often in lower-impact/hard-to-access journals
- No human RCTs for any indication; the human peripheral-nerve claim is an unreferenced review/vendor assertion (Grade D for humans)
- No validated human dose or safety dataset; injectable research-chemical contamination/sterility risk; hypothesis-grade mechanism
- Best for
- Seeing how a genuine but single-lab animal finding is honestly graded below replicated evidence
- Pricing
- Not FDA-approved; research chemical only
Source: Turchaninova et al., Bull Exp Biol Med 2000 (PMID 11276314)
Feature comparison
| Feature | ARA-290 (Cibinetide) | Cerebrolysin | BPC-157 | Cortagen |
|---|---|---|---|---|
| Human RCT in neuropathy | Yes (Phase 2, double-blind) | Yes (one small peripheral RCT) | No (none completed) | No (none) |
| Objective nerve-regeneration endpoint | Yes (corneal + skin fibers) | No (VAS pain symptom) | Animal only (function/EMG/histology) | Animal only (growth/conduction) |
| Independent replication | Single research network | Sponsor-correlated; contested (CNS) | Consistent multi-model (rat) | Single lab / single network |
| Feature | ARA-290 (Cibinetide) | Cerebrolysin | BPC-157 | Cortagen |
|---|---|---|---|---|
| FDA status | Orphan/Fast Track designation (not approved) | Not approved in U.S. (approved abroad) | Unsettled 2026 compounding status | Not on FDA bulk lists |
| WADA status | Prohibited (S2.1) | Likely S0 catch-all | Prohibited (S0) | Likely S0 catch-all |
Frequently asked
Is any peptide proven to repair nerves in humans?
Only partially. ARA-290 (cibinetide) is the sole peptide with double-blind, placebo-controlled human trials showing objective small-nerve-fiber regeneration — increased corneal nerve fiber area and skin GAP-43+ regenerating fibers at 4 mg subcutaneous daily. But this is Phase 2 evidence in sarcoidosis and diabetic small-fiber neuropathy only, never advanced to Phase 3 or approval. No peptide here is a proven cure for nerve injury, and none is FDA-approved for it. BPC-157 and Cortagen have animal data but no human nerve trials, and Cerebrolysin's peripheral-neuropathy evidence is a single small symptom-only study.
Does BPC-157 actually heal nerve damage?
In rats, the signal is real and unusually consistent: BPC-157 accelerated sciatic-nerve regeneration across functional walking recovery, EMG motor action potentials, and histology, and improved recovery in a spinal-cord-injury model out to 360 days. In humans, however, there are no completed nerve-injury trials, no validated pharmacokinetics, and only a couple dozen subjects studied in uncontrolled safety pilots. Any human 'nerve repair' claim is therefore extrapolation from rodent findings, and PeptideVox grades BPC-157 C (preclinical only) for this use. The first registered Phase 2 RCT is for hamstring strain, not nerve injury.
Can Cerebrolysin treat diabetic neuropathy?
The directly on-topic human evidence is one small German double-blind trial (about 25 patients) reporting a roughly 34% pain reduction on the visual-analog scale over a 10-day course versus a non-significant placebo change. That is a modest, single-study symptom signal graded B at best, using a pain endpoint rather than nerve-regeneration. Cerebrolysin's much larger RCT base is for central nerve injury — stroke and TBI — where the independent 2023 Cochrane review found little to no functional benefit and a possible increase in non-fatal serious adverse events. Do not conflate the peripheral-neuropathy data with the contested CNS literature.
What about Cortagen for nerve regeneration?
The evidence is a single Russian lab's rat sciatic-nerve study, in which Cortagen at 10 micrograms per kilogram intramuscular for 10 days increased the growth rate and conduction velocity of regenerating fibers by about 27% and 40% respectively. It is genuinely interesting but unreplicated outside its originating research group, and there are no human trials for any indication. The frequently repeated claim that Cortagen restores human peripheral nerve traces to unreferenced review or vendor material, not a controlled trial — so any human nerve-recovery claim should be read as Grade D. PeptideVox grades the animal nerve data C.
Are these peptides legal and safe to use for my neuropathy?
None is an FDA-approved neuropathy treatment. Most are sold only as research chemicals 'not for human use,' and ARA-290 and BPC-157 are prohibited in sport at all times under WADA. Several lack any long-term human safety data, and pro-angiogenic or regenerative mechanisms raise theoretical caution in active or prior malignancy. This article is informational only and is not medical advice or a protocol. Discuss any nerve condition with a licensed clinician, and prioritize addressing the underlying driver — glucose control, B12 and toxin status, mechanical compression, autoimmune triggers — over unproven peptides.
Do peptides replace standard neuropathy medications?
No. There is no peptide disease-modifying therapy approved for diabetic or other peripheral neuropathy as of 2026, and no head-to-head trial shows any peptide outperforming guideline care. Standard evidence-based management remains glycemic control in diabetes plus agents such as duloxetine, pregabalin, and gabapentin for neuropathic pain. From a functional, root-cause perspective, the most defensible nerve-supportive strategy is to correct the driver of the damage while recognizing that the peptides here range from a modest early human signal (ARA-290) down to single-lab animal data (Cortagen). None substitutes for a clinician-directed plan.